


## Dipotassium glycyrrhizinate

<b>Cat. No.:</b>	HY-N0184A		
<b>CAS No.:</b>	68797-35-3		
<b>Molecular Formula:</b>	C <sub>42</sub> H <sub>61</sub> KO <sub>16</sub>		
<b>Molecular Weight:</b>	861.02		
<b>Target:</b>	Virus Protease		
<b>Pathway:</b>	Anti-infection		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (58.07 mM; Need ultrasonic)  
 DMSO : 5 mg/mL (5.81 mM; Need ultrasonic)

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.1614 mL	5.8071 mL	11.6141 mL
	5 mM	0.2323 mL	1.1614 mL	2.3228 mL
	10 mM	0.1161 mL	0.5807 mL	1.1614 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Dipotassium glycyrrhizinate is a natural compound, inhibits atopic dermatitis-related gene expression with anti-inflammatory activity<sup>[1]</sup>.

### CUSTOMER VALIDATION

- Cell Prolif. 2020 May 17;e12829.
- Front Cell Dev Biol. 2020 Aug 11;8:713.
- Aging (Albany NY). 2019 Jul 7;11(13):4323-4337.
- ACS Chem Neurosci. 2020 Mar 18;11(6):979-993.
- Evid-Based Compl Alt. 2020 May.

---

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Lee SH, et al. Ameliorating effect of dipotassium glycyrrhizinate on an IL-4- and IL-13-induced atopic dermatitis-like skin-equivalent model. Arch Dermatol Res. 2019 Mar;311(2):131-140.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA